Compare Pfizer Inc (PFE) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

TLT trades at $83.66, down 1.02% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The ETF has experienced significant investor attention amid fixed income market resurgence, with recent dividend payments of $0.32-$0.34. Long-term Treasury bonds face headwinds from inflation concerns and potential Fed policy shifts, though current yields offer improved income potential compared to pre-crisis levels.

TLT presents a contrarian opportunity with starting yields four to five times higher than pre-2022 levels, but faces duration risk if interest rates remain elevated. The ETF's performance remains sensitive to Federal Reserve policy decisions and inflation trajectory, with institutional flows indicating renewed interest in fixed income assets despite recent volatility.